Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

What you feel with this company ? Are you willing to
Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887
Last $58.80 USD
Change Today +0.19 / 0.32%
Volume 5.9M
As of 8:04 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/21/14 - $59.50
52 Week Low
06/5/14 - $46.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

'Mom Turned Into a Monster': 10,000 Seniors Go Missing in Japan
Bristol-Myers Immune Drug Improves Lung Cancer Survival
Prudential Financial Takes Risk on $2.2 Billion L&G Portfolio
Bristol-Myers Tops Estimates on Strong Drug Sales
AstraZeneca, Bristol-Myers Won’t Face Kickback Lawsuit

bristol-myers squibb co (BMY) Related News

White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?
It's Not Just Disruption: More Management Wisdom You Should Doubt
'Miracle' Data Could Lead to Cancer Cures

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Announces Favorable Data from Hepatitis C Virus Trial

Bristol-Myers Squibb Company has announced favorable data from the UNITY Trial program investigating a 12-week regimen of its all-oral daclatasvir, or DCV, TRIO regimen, a fixed-dose combination of daclatasvir with asunaprevir, or ASV, and beclabuvir, or BCV, in patients with genotype 1 hepatitis C virus, or HCV. The primary endpoint for both studies was the percentage of patients who achieved cure, defined as HCV RNA. The open-label UNITY-1 study evaluated a 12-week regimen of the DCV-TRIO without ribavirin in treatment-naive and -experienced non-cirrhotic patients. Non-cirrhotic treatment-naive patients (n=312) and treatment-experienced patients (n=103) received the DCV-TRIO fixed-dose combination in one pill twice daily for 12 weeks, with 24 weeks of follow-up. The majority of the patients (73%) were genotype 1a, and 91% of all patients achieved SVR12. 92% of treatment-naive patients and 89% of treatment-experienced patients achieved cure, without the use of ribavirin. In the UNITY-2 study, both cirrhotic treatment-naive and treatment-experienced patients received the DCV-TRIO fixed-dose combination, one arm without ribavirin (n=102) and one with ribavirin (n=100). The study was double-blinded to ribavirin, and the majority of the patients (74%) were genotype 1a. The study showed 96% of all patients who received the DCV-TRIO with ribavirin achieved SVR12, and 90% of those who received the DCV-TRIO without ribavirin achieved SVR12.

Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA(TM)-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors -- Apixaban) studies. Andexanet alfa produced rapid and nearly complete reversal (by approximately 94%, p value < 0.0001) of the anticoagulant effect of Eliquis (apixaban) in healthy volunteers ages 50-75. This first part of the Phase 3 ANNEXA-A trial achieved all of its primary and secondary endpoints with statistical significance (p value>< 0.0001). The trial included 33 subjects, with 24 randomized to andexanet alfa and nine to placebo. In the study, two to five minutes after completion of a bolus dose of andexanet alfa, the anticoagulant activity of Eliquis was reversed by approximately 94% (p value>< 0.0001) compared with placebo as measured by anti-Factor Xa activity. Every subject treated with andexanet alfa had between 90 and 96% reversal of the anticoagulant activity of Eliquis. The reversal of anti-Factor Xa activity correlated with a significant reduction in the level of free, unbound Eliquis in the plasma, consistent with the mechanism of action of andexanet alfa. Additionally, andexanet alfa restored thrombin generation to baseline normal levels (prior to Eliquis therapy). In this study, no serious adverse events, thrombotic events, or antibodies to Factor X or Xa were reported following andexanet alfa administration. Mild infusion reaction was reported in three subjects>

Bristol-Myers Squibb to Invest Around €720 Million in New Plant in Dublin

Bristol-Myers Squibb has announced it is to invest around €720 million in a new plant in Dublin that will see the creation of 350-400 highly skilled jobs. The new 30,000 sq.m facility at Cruiserath near Blanchardstown will see the manufacture of a range of biologic drugs. The construction phase will see the creation of a further 1,000 temporary jobs. The new plant will be built on the grounds of the company's existing manufacturing site in the area.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $58.80 USD +0.19

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $67.36 USD +2.17
Actavis plc $259.75 USD +1.26
AstraZeneca PLC 4,741 GBp +30.00
Celgene Corp $108.20 USD +0.85
Novo Nordisk A/S kr265.80 DKK +2.00

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 36.1x
Price/Sales 6.1x
Price/Book 6.4x
Price/Cash Flow 35.9x
TEV/Sales 5.1x

Sponsored Financial Commentaries

Sponsored Links

Bristol-Myers Squibb’s ZymoGenetics R&D Facility Earns LEED Silver Certification from U.S. Green Building Council
[at noodls] - Since its founding 100 years ago, the historic Lake Union Steam Plant, now home to Bristol-Myers Squibb's ZymoGenetics R&D subsidiary, has been a symbol of economic and civic importance to the Eastlake ...